Esomeprazole magnesium - Generic Drug Details

What are the generic sources for esomeprazole magnesium and what is the scope of patent protection?

Esomeprazole magnesium is the generic ingredient in five branded drugs marketed by Alkem Labs Ltd, Amneal Pharms Ny, Aurobindo Pharma Ltd, Cipla, Cisen, Cspc Ouyi, Dr Reddys, Ethypharm, Glenmark Speclt, Granules, Graviti Pharms, Guangzhou Novaken, Hec Pharm, Hetero Labs Ltd Iii, Indchemie Health, Lannett Co Inc, Macleods Pharms Ltd, Mylan, Prinston Inc, Sun Pharm, Torrent, Zhejiang Yongtai, Zydus Pharms, Astrazeneca, Aurobindo Pharma, Guardian Drug, Marksans Pharma, Perrigo R And D, Pharmobedient, Astrazeneca Lp, P And L, Dexcel, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Sciegen Pharms, and Horizon, and is included in sixty-one NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Esomeprazole magnesium has four patent family members in three countries.

There are fifty-nine drug master file entries for esomeprazole magnesium. One hundred and ten suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for esomeprazole magnesium

International Patents:	4
US Patents:	2
Tradenames:	5
Applicants:	36
NDAs:	61
Drug Master File Entries:	59
Finished Product Suppliers / Packagers:	110
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	24
Patent Applications:	2,780
Drug Prices:	Drug price trends for esomeprazole magnesium
Drug Sales Revenues:	Drug sales revenues for esomeprazole magnesium
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for esomeprazole magnesium
What excipients (inactive ingredients) are in esomeprazole magnesium?	esomeprazole magnesium excipients list
DailyMed Link:	esomeprazole magnesium at DailyMed

See drug prices for esomeprazole magnesium

See drug sales revenues for esomeprazole magnesium

Recent Clinical Trials for esomeprazole magnesium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jiangsu Sinorda Biomedicine Co., Ltd	PHASE1
Livzon Pharmaceutical Group Inc.	PHASE3
Bio-innova Co., Ltd	PHASE1

See all esomeprazole magnesium clinical trials

Generic filers with tentative approvals for ESOMEPRAZOLE MAGNESIUM

Applicant	Application No.	Strength	Dosage Form
		EQ 20MG BASE;500MG	TABLET, DELAYED RELEASE;ORAL
		EQ 20MG BASE;375MG	TABLET, DELAYED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for esomeprazole magnesium

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Cytochrome P450 2C19 Inhibitors Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for esomeprazole magnesium

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for ESOMEPRAZOLE MAGNESIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	2.5 mg and 5 mg	021957	1	2018-09-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	10 mg	022101	1	2018-07-06
NEXIUM 24HR	Delayed-release Capsules	esomeprazole magnesium	20 mg	204655		2014-04-24
NEXIUM	Delayed-release for Oral Suspension	esomeprazole magnesium	20 mg and 40 mg	021957	1	2013-08-01
NEXIUM	Delayed-release Capsules	esomeprazole magnesium	20 mg and 40 mg	021153	1	2005-08-05

US Patents and Regulatory Information for esomeprazole magnesium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zhejiang Yongtai	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	217022-001	Dec 27, 2023	AB	RX	No	No
Graviti Pharms	ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	213486-001	Mar 19, 2021	AB	RX	No	No
Sciegen Pharms	NAPROXEN AND ESOMEPRAZOLE MAGNESIUM	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	217738-001	Oct 11, 2023	AB	RX	No	No

Expired US Patents for esomeprazole magnesium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-002	Oct 20, 2006
Astrazeneca	NEXIUM	esomeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	021957-004	Dec 15, 2011
Astrazeneca	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153-001	Feb 20, 2001

International Patents for esomeprazole magnesium

Country	Patent Number	Title	Estimated Expiration
Australia	2017285390	Stable orally disintegrating pharmaceutical compositions
World Intellectual Property Organization (WIPO)	2017216789
European Patent Office	3932396	COMPOSITIONS PHARMACEUTIQUES STABLES À DÉSINTÉGRATION ORALE (STABLE ORALLY DISINTEGRATING PHARMACEUTICAL COMPOSITIONS)

Supplementary Protection Certificates for esomeprazole magnesium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214

Esomeprazole magnesium Market Analysis and Financial Projection

Last updated: February 12, 2026

What are the current market dynamics for Esomeprazole Magnesium?

Esomeprazole Magnesium is a proton pump inhibitor (PPI) indicated for acid-related gastrointestinal conditions, such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The drug holds a significant position within the PPI segment, which dominates the global acid suppression therapeutic market.

Market Size and Growth Trends

The global PPI market, driven primarily by Esomeprazole Magnesium, was valued at approximately USD 9.4 billion in 2022. The market is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2028, reaching an estimated USD 12.2 billion by 2028. This growth aligns with increasing prevalence of gastroesophageal conditions, rising aging populations, and awareness of gastrointestinal health.

Competitive Positioning and Market Share

Esomeprazole Magnesium accounts for roughly 35% of the PPI market, positioning it as the second most prescribed PPI after Omeprazole. Its premium status partly stems from higher bioavailability and fewer drug-drug interactions relative to other PPIs. Major manufacturers include AstraZeneca, Novartis, and Teva Pharmaceuticals, each controlling significant market shares through branded and generic formulations.

Pricing and Insurance Dynamics

Pricing strategies differ across regions. In the United States, brand-name Esomeprazole (Nexium) can reach USD 300-400 per month without insurance, whereas generics are priced between USD 10 and USD 50. Insurance coverage expands access; however, shifts toward generic prescribing put pressure on profit margins, especially for branded variants.

Regulatory Environment

Regulatory bodies like FDA and EMA have approved various formulations, including intravenous (IV) and oral tablets. Patent protections for Nexium expired in 2014 in the US, opening markets for generics. Other regions still hold patent protections until 2024-2026, influencing market entry timing and competitive dynamics.

Epidemiological Drivers

The increasing global burden of GERD, peptic ulcer disease, and Zollinger-Ellison syndrome sustains demand. The WHO estimates that GERD affects up to 20% of the Western population, with rising incidence in Asia-Pacific markets. Obesity and lifestyle factors drive prevalence, especially in developed economies.

Impact of Cancer and Lifestyle Trends

Lifestyle changes have led to increased use of PPIs for off-label indications and overuse concerns. The risk of long-term side effects, such as osteoporosis and renal disease, influences prescribing patterns and patient adherence.

What is the financial trajectory forecast for Esomeprazole Magnesium?

Revenue Projections

From 2023 to 2028, global revenues for Esomeprazole Magnesium are expected to grow from USD 3.3 billion to approximately USD 4.4 billion, assuming stable market expansion and generic competition in mature markets. The growth stems from increasing disease prevalence, expanding indications (including off-label uses), and rising adoption of IV formulations in hospital settings.

Key Revenue Drivers

• Patent expiries: Opportunities for generics increase after patent lifespans end, reducing drug prices. The US patent expiry (~2014) caused a sharp revenue decline for the branded drug but created growth opportunities for generics.
• Market penetration in emerging economies: Growing healthcare infrastructure enables wider access, leading to higher volume sales.
• New formulations: Extended-release, IV, and pediatric formulations diversify revenue streams.

Profitability Outlook

Branded versions like Nexium have been declining in profitability since patent expiry. Generics have significantly lower margins but maintain volume growth. In 2022, the operating margins for brand-name Nexium hovered around 20%, while generics hovered near 15%. Price erosion remains the primary challenge.

R&D Investment and Pipeline

R&D investments focus on improved delivery systems, combination therapies, and biomarker-driven personalized medicine. Currently, no major Phase III pipeline drugs target new indications for Esomeprazole Magnesium, limiting future pipeline revenue.

Licensing and Partnerships

Early-stage licensing deals have included Takeda and Mylan, which focus on developing negative injection and combination products. These partnerships aim to extend lifecycle revenues and position for markets with patent protections.

Market Risks impacting Financial Trajectory

• Generic competition: Accelerated by patent expiries, leading to price declines.
• Regulatory changes: Stringent drug safety regulations can delay launches and increase costs.
• Market saturation: Particularly in developed countries, limits further growth unless new indications or formulations expand usage.

What are the key factors affecting future market and financial performance?

• Price erosion: Generics dominate, constraining profit margins.
• Increased healthcare access in emerging markets: Expanding middle-class populations improve volume but pressure pricing.
• Shift toward personalized medicine: Developing targeted therapies could cannibalize traditional PPI markets.
• Regulatory pressures: Potential restrictions on long-term PPI use could impact sales volumes.
• Emergence of alternative therapies: Novel acid suppressants or combination drugs may replace PPIs in some indications.

What strategic considerations should investors and R&D entities prioritize?

• Investing in formulations with patent protections or combination products.
• Monitoring patent cliffs in key markets to identify timing for generic entry.
• Supporting research into novel pathways for acid suppression or indications beyond GERD.
• Analyzing regional market expansion opportunities, especially in Asia-Pacific and Latin America.
• Navigating regulatory landscapes to accelerate approvals and reduce time-to-market for generics and biosimilars.

Key Takeaways

• Esomeprazole Magnesium remains a leading PPI with substantial global sales, but its trajectory faces pressure from patent expiries and generics.
• Revenue is projected to grow modestly through emerging markets and new formulations, though profitability declines alongside generic competition.
• Market expansion in emerging economies and pipeline developments could provide upside, but regulatory and competitive risks are significant.
• Companies should focus on lifecycle management, regional expansion, and innovation in delivery systems to sustain long-term margins.
• The future of Esomeprazole Magnesium hinges on balancing patent protections, pricing pressures, and evolving clinical landscape.

FAQs

Q1: When did the patent for Nexium (Esomeprazole Magnesium) expire in the US?
A1: The patent expired in 2014, enabling the entry of generic versions.

Q2: What are the main competitors to Esomeprazole Magnesium?
A2: Omeprazole (Prilosec), Lansoprazole (Prevacid), and Pantoprazole (Protonix) are key competitors, with Omeprazole leading the market.

Q3: How does the patent expiry impact the market share of Esomeprazole Magnesium?
A3: Patent expiry leads to a surge in generic availability, reducing the brand's market share and profitability.

Q4: Which regions represent growth opportunities for Esomeprazole Magnesium?
A4: Asia-Pacific and Latin America show growth potential due to rising healthcare infrastructure and increasing disease prevalence.

Q5: Are there notable ongoing developments for new indications or formulations?
A5: Current focus includes formulations like IV versions and combination therapies; no substantial pipeline for new indications is publicly announced.

---

Sources:

1. MarketsandMarkets, "Proton Pump Inhibitors Market," 2023.
2. EvaluatePharma, "Global Oncology and Gastrointestinal Drugs Market," 2022.
3. U.S. FDA, "Nexium Patent and Exclusivity Details," 2014.
4. IQVIA, "Global Gastrointestinal Drugs Report," 2022.
5. WHO, "Gastroesophageal Reflux Disease Prevalence," 2021.